Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Theo J.S. Offerman"'
Autor:
Wim H. van Harten, Theo J.S. Offerman, Valesca P. Retèl, Andreas Ziegler, Giorgia Romagnoli, Nora Franzen
The high cost of many new anticancer medicines significantly impedes breakthrough discoveries from reaching patients. A commonly heard refrain is that high prices are necessary to compensate for the high costs of research and development (R&D). Yet,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::891e76aac05560c4c59fc4e6158a80a9
https://doi.org/10.1158/2159-8290.c.6549631
https://doi.org/10.1158/2159-8290.c.6549631
Autor:
Wim H. van Harten, Theo J.S. Offerman, Valesca P. Retèl, Andreas Ziegler, Giorgia Romagnoli, Nora Franzen
Supplementary DataBrief description of important policy proposals to reduce treatment prices in oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3122599571a6398e3a039d5cae31defa
https://doi.org/10.1158/2159-8290.22541398.v1
https://doi.org/10.1158/2159-8290.22541398.v1
Autor:
Nora Franzen, Giorgia Romagnoli, Andreas Ziegler, Valesca P. Retèl, Theo J.S. Offerman, Wim H. van Harten
Publikováno v:
Cancer Discovery, 12(2), 299-302. American Association for Cancer Research Inc.
The high cost of many new anticancer medicines significantly impedes breakthrough discoveries from reaching patients. A commonly heard refrain is that high prices are necessary to compensate for the high costs of research and development (R&D). Yet,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0d8257beebeaaf6ca86bfb2d39a77fd
https://pure.eur.nl/en/publications/d02e5858-7710-4346-b6f7-b4dc2d06b463
https://pure.eur.nl/en/publications/d02e5858-7710-4346-b6f7-b4dc2d06b463
Autor:
Nora Franzen, Andreas Ziegler, Giorgia Romagnoli, Valesca P. Retèl, Theo J.S. Offerman, Wim H. van Harten
Publikováno v:
Cancer Research Communications. 2:49-57
The high prices of innovative medicines endanger access to care worldwide. Sustainable prices need to be affordable while sufficiently incentivizing research and development (R&D) investments. A proposed solution is increased transparency. Proponents
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::892218711aa13a4bfb1d1013b63c1d34
https://doi.org/10.1158/2767-9764.crc-21-0031
https://doi.org/10.1158/2767-9764.crc-21-0031